DE60303238T2 - Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten - Google Patents

Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten Download PDF

Info

Publication number
DE60303238T2
DE60303238T2 DE60303238T DE60303238T DE60303238T2 DE 60303238 T2 DE60303238 T2 DE 60303238T2 DE 60303238 T DE60303238 T DE 60303238T DE 60303238 T DE60303238 T DE 60303238T DE 60303238 T2 DE60303238 T2 DE 60303238T2
Authority
DE
Germany
Prior art keywords
pyrimidinyl
amino
benzyl
acetic acid
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303238T
Other languages
German (de)
English (en)
Other versions
DE60303238D1 (de
Inventor
Tai Ly Nara-shi Nara-ken Wie
Yuji Nara-shi Nara-ken Koriyama
Takashi Nara-shi Nara-ken Yoshino
Hiroki Nara-shi Nara-ken Sato
Kazuho Yamato Koriyama-shi Nara-ken Tanaka
Hiromi Sorakui-gun Kyoto-fu Sugimoto
Yoshihisa Nara-shi Nara-ken Manabe
Kevin Kobe-shi Hyogo-ken Bacon
Klaus Kobe-shi Hyogo-ken Urbahns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of DE60303238D1 publication Critical patent/DE60303238D1/de
Application granted granted Critical
Publication of DE60303238T2 publication Critical patent/DE60303238T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60303238T 2003-04-25 2003-04-25 Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten Expired - Lifetime DE60303238T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

Publications (2)

Publication Number Publication Date
DE60303238D1 DE60303238D1 (de) 2006-04-06
DE60303238T2 true DE60303238T2 (de) 2006-09-14

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60303238T Expired - Lifetime DE60303238T2 (de) 2003-04-25 2003-04-25 Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004030907T Expired - Lifetime DE602004030907D1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004030907T Expired - Lifetime DE602004030907D1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Country Status (32)

Country Link
US (2) US7812160B2 (enExample)
EP (2) EP1471057B1 (enExample)
JP (2) JP4671955B2 (enExample)
KR (1) KR101110491B1 (enExample)
CN (2) CN101914065A (enExample)
AR (1) AR043885A1 (enExample)
AT (2) ATE316077T1 (enExample)
AU (1) AU2004233966B2 (enExample)
BR (1) BRPI0409733A (enExample)
CA (1) CA2523439C (enExample)
CL (1) CL43596B (enExample)
CY (1) CY1111295T1 (enExample)
DE (2) DE60303238T2 (enExample)
DK (2) DK1471057T3 (enExample)
DO (1) DOP2004000875A (enExample)
ES (2) ES2257616T3 (enExample)
GT (1) GT200400079A (enExample)
HN (1) HN2004000129A (enExample)
IL (1) IL171566A (enExample)
MX (1) MXPA05011399A (enExample)
MY (1) MY147984A (enExample)
NO (1) NO20055588L (enExample)
NZ (1) NZ543693A (enExample)
PE (1) PE20050143A1 (enExample)
PL (1) PL1633726T3 (enExample)
PT (2) PT1471057E (enExample)
RU (1) RU2361865C2 (enExample)
SI (1) SI1633726T1 (enExample)
TW (1) TWI353980B (enExample)
UY (1) UY28286A1 (enExample)
WO (1) WO2004096777A1 (enExample)
ZA (1) ZA200508722B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
DK1718649T3 (da) * 2004-01-31 2009-08-24 Actimis Pharmaceuticals Inc Imidazo[1,2-c]pyrimidinyleddikesyrederivater
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
EP1817282B1 (en) 2004-11-23 2011-07-20 AstraZeneca AB Phenoxyacetic acid derivatives useful for treating respiratory diseases
ATE524182T1 (de) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-substituierte pyrazinsulfonamide als crth2- hemmer
WO2006125784A1 (en) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Tricyclic spiro derivatives as crth2 modulators
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP1937632A1 (en) * 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
WO2007143745A2 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8278310B2 (en) * 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist
EP2170838A1 (en) * 2007-06-21 2010-04-07 Actimis Pharmaceuticals, Inc., Particulates of a crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
KR20100061746A (ko) 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Crth2 길항제로서의 2-s-벤질 치환된 피리미딘
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Crth2アンタゴニストとしての同位体富化されたピリミジン−5−イル酢酸誘導体
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
BRPI0923592A2 (pt) * 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
JP2012517405A (ja) 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
WO2010092043A1 (en) 2009-02-12 2010-08-19 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Dp2 길항제 및 이의 용도
JP2013512242A (ja) * 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−5−イル酢酸誘導体のコリン塩の多形体を調製する方法
MX2012007927A (es) 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
ES2545865T3 (es) 2010-01-27 2015-09-16 Boehringer Ingelheim International Gmbh Compuestos de pirazol como antagonistas de CRTH2
EP2586772A4 (en) 2010-06-23 2013-11-13 Taisho Pharmaceutical Co Ltd isoquinoline
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
KR102090990B1 (ko) 2010-10-20 2020-03-19 에스더블유아이엠씨 엘엘씨 머플러 등급의 스테인리스 강을 포함하는 넓은 범위의 코팅 및 비코팅 기재에의 접착성이 향상된 수계 코팅 시스템
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
JP5988253B2 (ja) 2011-05-16 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング [4,6−ビス−ジメチルアミノ−2−[4−(4−トリフルオロメチルベンゾイル−アミノ)ベンジル]ピリミジン−5−イル]酢酸の調製方法
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
BR9712000A (pt) * 1996-09-06 1999-08-24 Nippon Kayaku Kk Derivados de acetamida sais dos mesmos composi-Æo farmac-utica inibidores de protease de quimase de desgranula-Æo de mastÄcitos ou de libera-Æo de histamina de mastÄcitos e de ativa-Æo de eosinÄfilo ou de libera-Æo de oxig-nio ativo de eosinÄfilo e processo para produzir os dervados de acetamida
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CN1239485C (zh) * 2000-05-22 2006-02-01 里奥制药有限公司 作为IL-1β和TNF-α抑制剂的二苯酮类
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EP2170838A1 (en) 2007-06-21 2010-04-07 Actimis Pharmaceuticals, Inc., Particulates of a crth2 antagonist
US8278310B2 (en) 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist

Also Published As

Publication number Publication date
NO20055588D0 (no) 2005-11-25
KR101110491B1 (ko) 2012-01-31
RU2361865C2 (ru) 2009-07-20
CA2523439C (en) 2012-06-19
PT1471057E (pt) 2006-05-31
EP1633726B1 (en) 2011-01-05
US7812160B2 (en) 2010-10-12
DE602004030907D1 (de) 2011-02-17
UY28286A1 (es) 2004-11-30
CA2523439A1 (en) 2004-11-11
DK1471057T3 (da) 2006-05-15
ES2358424T3 (es) 2011-05-10
TWI353980B (en) 2011-12-11
PL1633726T3 (pl) 2011-06-30
AU2004233966A1 (en) 2004-11-11
EP1633726A1 (en) 2006-03-15
DE60303238D1 (de) 2006-04-06
JP4671955B2 (ja) 2011-04-20
SI1633726T1 (sl) 2011-04-29
IL171566A (en) 2011-03-31
ATE494279T1 (de) 2011-01-15
US7960393B2 (en) 2011-06-14
BRPI0409733A (pt) 2006-05-09
ES2257616T3 (es) 2006-08-01
US20100322980A1 (en) 2010-12-23
NZ543693A (en) 2009-05-31
CN101914065A (zh) 2010-12-15
AU2004233966B2 (en) 2010-11-11
RU2005136655A (ru) 2006-06-10
TW200505873A (en) 2005-02-16
ZA200508722B (en) 2006-12-27
CN1809539A (zh) 2006-07-26
CN1809539B (zh) 2012-05-09
US20070129355A1 (en) 2007-06-07
ATE316077T1 (de) 2006-02-15
CL43596B (es) 2005-03-18
NO20055588L (no) 2006-01-24
EP1471057B1 (en) 2006-01-18
CY1111295T1 (el) 2015-08-05
JP5161290B2 (ja) 2013-03-13
EP1471057A1 (en) 2004-10-27
WO2004096777A1 (en) 2004-11-11
AR043885A1 (es) 2005-08-17
MXPA05011399A (es) 2006-05-31
DK1633726T3 (da) 2011-03-28
HN2004000129A (es) 2009-05-14
HK1095320A1 (en) 2007-05-04
MY147984A (en) 2013-02-28
JP2006524645A (ja) 2006-11-02
PT1633726E (pt) 2011-02-22
GT200400079A (es) 2004-11-30
PE20050143A1 (es) 2005-04-01
JP2011068657A (ja) 2011-04-07
KR20060089622A (ko) 2006-08-09
DOP2004000875A (es) 2004-10-31

Similar Documents

Publication Publication Date Title
EP1471057B1 (en) Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
JP4996257B2 (ja) イミダゾ[1,2−c]ピリミジニル酢酸誘導体
EP2090571B1 (de) Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
DE60022386T2 (de) Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
EP2027107B1 (de) 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen
AU2009239794A1 (en) Substituted pyrimidin-5-carboxamides 281
DE60111752T2 (de) 7-oxopyridoryrimidine
DE60318694T2 (de) 4-(pyrrolopyrimidin-6-yl)benzolsulfonamidderivate
DE69404627T2 (de) Pyrimidon-derivate, die an einem stickstoff-enthaltenden heterocyclus kondensiert sind und ihre verwendung als angiotensin ii antagonisten
DD220780A5 (de) Verfahren zur herstellung von 5-subst.-(1,2,4) triazolo (1,5-c) pryimidin-2-aminen
EP0589335B1 (de) N1-Substituierte 1H-1,2,3-Triazolo[4,5-d]pyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel
HK1095320B (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ACTIMIS PHARMACEUTICALS, INC., SAN DIEGO, CALI, US